RecruitingPhase 2NCT07224100
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Studying B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Ryan Cassaday, MDFred Hutch/University of Washington Cancer Consortium
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07224100 on ClinicalTrials.gov